ACT Capital Partners, L.P.’s Arcturus Therapeutics ARCT Stock Holding History

ACT Capital Partners, L.P.’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$308K	Buy	+22,500	New	+$235K	0.2%	44

Other funds holding ARCT

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Empire Life Investments Toronto, Ontario, Canada $1.83B AUM 33.18% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

ACT Capital Partners, L.P.'s ARCT Position: Q3 2026 in Review

ACT Capital Partners, L.P. opened a new position in Arcturus Therapeutics (ARCT) in Q3 2026: 22,500 shares worth $308K. The stake represents 0.2% of the portfolio and ranks #44 among its holdings.

56 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.

ACT Capital Partners, L.P. held 22,500 shares of Arcturus Therapeutics worth $308K as of Q3 2026.
Arcturus Therapeutics was a new ACT Capital Partners, L.P. position in Q3 2026.
Arcturus Therapeutics made up 0.2% of ACT Capital Partners, L.P.'s portfolio in Q3 2026, its #44 holding.
56 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.

Based on ACT Capital Partners, L.P.'s 13F filing for Q3 2026, filed 6 Nov 2026.